MedTrace Logo

A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy

NCT00785928 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 158

Last updated 2018-07-10

Study results available
· View outcomes & findings →

Summary

To assess the efficacy of LY2127399 versus placebo using American College of Rheumatology (ACR)50 response scale at 24 weeks

Conditions

Interventions

BIOLOGICAL

LY2127399

Administered SC every 4 weeks over a 24-week period (Weeks 0, 4, 8, 12, 16, and 20).

DRUG

Placebo

Administered subcutaneously (SC) every 4 weeks over a 24-week period (Weeks 0, 4, 8, 12, 16, and 20).

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLy (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2010-01-31
Completion
2010-12-31

Countries

  • United States
  • Argentina
  • Australia
  • Chile
  • Germany
  • Hungary
  • India
  • Mexico
  • Poland
  • Romania
  • Slovakia
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00785928 on ClinicalTrials.gov